Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Novocure Ltd (NVCR) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Novocure Ltd. Table 2 shows the detailed insider transactions. This company's CIK number is 1645113.
Total stock buying since 2015: $1,955,939.
Total stock sales since 2015: $562,447,534.
Total stock option exercises since 2015: $174,081,556.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 20,000 | $231,540 | 51,153 | $1,003,641 | 0 | $0 |
| 2024 | 0 | $0 | 7,270 | $142,081 | 124,373 | $2,838,191 |
| 2023 | 0 | $0 | 355,631 | $37,028,303 | 267,623 | $2,779,194 |
| 2022 | 0 | $0 | 201,400 | $16,501,140 | 85,297 | $820,884 |
| 2021 | 4,974 | $501,095 | 305,402 | $53,648,487 | 158,778 | $9,089,465 |
| 2020 | 4,200 | $357,054 | 952,731 | $97,931,468 | 1,050,394 | $38,728,371 |
| 2019 | 0 | $0 | 4,036,171 | $248,001,465 | 4,542,155 | $101,208,755 |
| 2018 | 0 | $0 | 2,245,603 | $61,035,178 | 1,568,421 | $10,066,548 |
| 2017 | 125,000 | $866,250 | 2,555,165 | $43,935,150 | 1,573,732 | $4,510,852 |
| 2016 | 0 | $0 | 879,076 | $3,220,621 | 2,350,974 | $4,039,109 |
| 2015 | 0 | $0 | 0 | $0 | 1,100 | $187 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 20,000 | $231,540 | 0 | $0 | 0 | $0 |
| 2025-06 | 0 | $0 | 5,994 | $103,679 | 0 | $0 |
| 2025-05 | 0 | $0 | 592 | $10,604 | 0 | $0 |
| 2025-03 | 0 | $0 | 4,848 | $89,965 | 0 | $0 |
| 2025-02 | 0 | $0 | 37,559 | $741,488 | 0 | $0 |
| 2025-01 | 0 | $0 | 2,160 | $57,905 | 0 | $0 |
| 2024-11 | 0 | $0 | 802 | $12,804 | 0 | $0 |
| 2024-10 | 0 | $0 | 810 | $12,791 | 0 | $0 |
| 2024-08 | 0 | $0 | 688 | $13,857 | 0 | $0 |
| 2024-06 | 0 | $0 | 2,892 | $69,084 | 124,373 | $2,838,191 |
| 2024-02 | 0 | $0 | 2,078 | $33,545 | 0 | $0 |
| 2023-11 | 0 | $0 | 382 | $4,832 | 175 | $2,005 |
| 2023-10 | 0 | $0 | 0 | $0 | 17,793 | $178,232 |
| 2023-09 | 0 | $0 | 1,450 | $31,634 | 0 | $0 |
| 2023-08 | 0 | $0 | 1,144 | $34,607 | 0 | $0 |
| 2023-03 | 0 | $0 | 92,118 | $7,006,740 | 0 | $0 |
| 2023-01 | 0 | $0 | 260,537 | $29,950,490 | 249,655 | $2,598,957 |
| 2022-12 | 0 | $0 | 0 | $0 | 2,000 | $14,300 |
| 2022-10 | 0 | $0 | 6,754 | $569,834 | 0 | $0 |
| 2022-09 | 0 | $0 | 137,455 | $11,873,560 | 49,653 | $355,014 |
| 2022-08 | 0 | $0 | 7,647 | $549,877 | 0 | $0 |
| 2022-06 | 0 | $0 | 407 | $28,331 | 0 | $0 |
| 2022-05 | 0 | $0 | 4,205 | $265,645 | 0 | $0 |
| 2022-03 | 0 | $0 | 40,981 | $2,913,515 | 5,040 | $68,191 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-29 | Brackmann Christoph (Chief Financial Officer) | Buy | 20,000 | 11.58 | 231,540 |
| 2025-06-03 | Stafford Kristin | Sale | 999 | 17.28 | 17,258 |
| 2025-06-03 | Ocean Allyson J | Sale | 999 | 17.29 | 17,268 |
| 2025-06-03 | Scannell Timothy J | Sale | 999 | 17.32 | 17,299 |
| 2025-06-03 | Vernon W Anthony | Sale | 999 | 17.35 | 17,329 |
| 2025-06-03 | Hung David | Sale | 999 | 17.30 | 17,279 |
| 2025-06-03 | Hilleman Jeryl L | Sale | 999 | 17.26 | 17,246 |
| 2025-05-03 | Paravasthu Mukund (Chief Operating Officer) | Sale | 592 | 17.91 | 10,604 |
| 2025-03-03 | Leonard Frank X (EVP, Pres., Novocure Oncology) | Sale | 2,527 | 18.54 | 46,840 |
| 2025-03-03 | Cordova Ashley (Chief Executive Officer) | Sale | 2,053 | 18.54 | 38,054 |
| 2025-03-03 | Weinberg Uri (Chief Innovation Officer) | Sale | 268 | 18.92 | 5,071 |
| 2025-02-28 | Paravasthu Mukund (Chief Operating Officer) | Sale | 368 | 18.28 | 6,728 |
| 2025-02-28 | Leonard Frank X (EVP, Pres., Novocure Oncology) | Sale | 2,770 | 18.28 | 50,646 |
| 2025-02-28 | Cordova Ashley (Chief Executive Officer) | Sale | 2,341 | 18.28 | 42,802 |
| 2025-02-28 | Weinberg Uri (Chief Innovation Officer) | Sale | 4,637 | 18.55 | 86,007 |
| 2025-02-27 | Paravasthu Mukund (Chief Operating Officer) | Sale | 1,646 | 20.23 | 33,306 |
| 2025-02-27 | Leupin Nicolas (Chief Medical Officer) | Sale | 991 | 20.23 | 20,052 |
| 2025-02-27 | Puri Michal Nath (Chief Human Resources Officer) | Sale | 1,387 | 20.23 | 28,065 |
| 2025-02-27 | Leonard Frank X (EVP, Pres., Novocure Oncology) | Sale | 12,266 | 20.23 | 248,202 |
| 2025-02-27 | Cordova Ashley (Chief Executive Officer) | Sale | 11,153 | 20.23 | 225,680 |
| 2025-01-11 | Paravasthu Mukund (Chief Operating Officer) | Sale | 2,160 | 26.81 | 57,905 |
| 2024-11-02 | Paravasthu Mukund (Chief Operating Officer) | Sale | 44 | 16.69 | 734 |
| 2024-11-01 | Paravasthu Mukund (Chief Operating Officer) | Sale | 160 | 15.88 | 2,540 |
| 2024-11-01 | Leonard Frank X (EVP, Pres., Novocure Oncology) | Sale | 598 | 15.94 | 9,530 |
| 2024-10-31 | Puri Michal Nath (Chief Human Resources Officer) | Sale | 810 | 15.79 | 12,791 |
| 2024-08-02 | Cordova Ashley (Chief Financial Officer) | Sale | 688 | 20.14 | 13,857 |
| 2024-06-05 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Option Ex | 124,373 | 22.82 | 2,838,191 |
| 2024-06-04 | Scannell Timothy J | Sale | 964 | 23.89 | 23,027 |
| 2024-06-04 | Vernon W Anthony | Sale | 964 | 23.89 | 23,032 |
| 2024-06-04 | Leung Gabriel | Sale | 964 | 23.89 | 23,025 |
| 2024-02-28 | Leonard Frank X (EVP, Pres., Novocure Oncology) | Sale | 2,078 | 16.14 | 33,545 |
| 2023-11-07 | Shah Pritesh (Chief Growth Officer) | Sale | 382 | 12.65 | 4,832 |
| 2023-11-02 | Cordova Ashley (Chief Financial Officer) | Option Ex | 175 | 11.46 | 2,005 |
| 2023-10-31 | Cordova Ashley (Chief Financial Officer) | Option Ex | 17,793 | 10.02 | 178,232 |
| 2023-09-01 | Cordova Ashley (Chief Financial Officer) | Sale | 883 | 21.82 | 19,264 |
| 2023-09-01 | Shah Pritesh (Chief Growth Officer) | Sale | 273 | 21.82 | 5,956 |
| 2023-09-01 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 294 | 21.82 | 6,414 |
| 2023-08-02 | Cordova Ashley (Chief Financial Officer) | Sale | 1,144 | 30.25 | 34,607 |
| 2023-03-07 | Leonard Frank X (President, CNS Cancers US) | Sale | 8,318 | 75.30 | 626,303 |
| 2023-03-03 | Burke William Patrick (Chief Human Resources Officer) | Sale | 593 | 76.16 | 45,162 |
| 2023-03-03 | Leonard Frank X (President, CNS Cancers US) | Sale | 7,350 | 76.90 | 562,815 |
| 2023-03-03 | Cordova Ashley (Chief Financial Officer) | Sale | 5,505 | 76.16 | 419,255 |
| 2023-03-03 | Shah Pritesh (Chief Growth Officer) | Sale | 21,421 | 76.16 | 1,631,401 |
| 2023-03-03 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 25,635 | 76.16 | 1,952,335 |
| 2023-03-02 | Burke William Patrick (Chief Human Resources Officer) | Sale | 281 | 75.28 | 21,153 |
| 2023-03-02 | Leonard Frank X (President, CNS Cancers US) | Sale | 4,951 | 75.48 | 374,380 |
| 2023-03-02 | Cordova Ashley (Chief Financial Officer) | Sale | 1,055 | 75.28 | 79,418 |
| 2023-03-02 | Shah Pritesh (Chief Growth Officer) | Sale | 937 | 75.28 | 70,535 |
| 2023-03-02 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 1,213 | 75.28 | 91,312 |
| 2023-03-01 | Burke William Patrick (Chief Human Resources Officer) | Sale | 755 | 76.36 | 57,653 |
| 2023-03-01 | Leonard Frank X (President, CNS Cancers US) | Sale | 1,684 | 76.36 | 128,593 |
| 2023-03-01 | Cordova Ashley (Chief Financial Officer) | Sale | 2,198 | 76.36 | 167,843 |
| 2023-03-01 | Shah Pritesh (Chief Growth Officer) | Sale | 1,923 | 76.36 | 146,844 |
| 2023-03-01 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 2,164 | 76.36 | 165,247 |
| 2023-01-05 | Leonard Frank X (President, CNS Cancers US) | Sale | 39,507 | 113.00 | 4,464,488 |
| 2023-01-05 | Leonard Frank X (President, CNS Cancers US) | Option Ex | 35,209 | 15.06 | 530,106 |
| 2023-01-05 | Weinberg Uri (Chief Science Officer) | Sale | 8,143 | 117.00 | 952,731 |
| 2023-01-05 | Weinberg Uri (Chief Science Officer) | Option Ex | 1,946 | 47.04 | 91,539 |
| 2023-01-05 | Shah Pritesh (Chief Commercial Officer) | Sale | 387 | 108.00 | 41,796 |
| 2023-01-05 | Danziger Asaf (Chief Executive Officer) | Sale | 212,500 | 115.25 | 24,491,475 |
| 2023-01-05 | Danziger Asaf (Chief Executive Officer) | Option Ex | 212,500 | 9.30 | 1,977,312 |
| 2022-12-02 | Cordova Ashley (Chief Financial Officer) | Option Ex | 2,000 | 7.15 | 14,300 |
| 2022-10-06 | Leonard Frank X (President, CNS Cancers US) | Sale | 6,754 | 84.37 | 569,834 |
| 2022-09-29 | Leonard Frank X (President, CNS Cancers US) | Sale | 6,754 | 77.35 | 522,421 |
| 2022-09-22 | Leonard Frank X (President, CNS Cancers US) | Sale | 13,508 | 77.00 | 1,040,116 |
| 2022-09-15 | Leonard Frank X (Chief Development Officer) | Sale | 61,355 | 88.66 | 5,439,425 |
| 2022-09-15 | Leonard Frank X (Chief Development Officer) | Option Ex | 27,585 | 7.15 | 197,230 |
| 2022-08-03 | Benaim Ely (Chief Medical Officer) | Sale | 5,959 | 72.55 | 432,295 |
| 2022-08-02 | Leonard Frank X (Chief Development Officer) | Sale | 414 | 69.66 | 28,838 |
| 2022-08-02 | Benaim Ely (Chief Medical Officer) | Sale | 437 | 69.66 | 30,440 |
| 2022-08-02 | Doyle William F (Executive Chairman) | Sale | 837 | 69.66 | 58,304 |
| 2022-06-10 | Hilleman Jeryl L | Sale | 407 | 69.61 | 28,331 |
| 2022-05-11 | Benaim Ely (Chief Medical Officer) | Sale | 2,135 | 61.25 | 130,768 |
| 2022-05-10 | Benaim Ely (Chief Medical Officer) | Sale | 2,070 | 65.16 | 134,877 |
| 2022-03-09 | Shah Pritesh (Chief Commercial Officer) | Sale | 3,669 | 71.19 | 261,196 |
| 2022-03-08 | Burke William Patrick (Chief Human Resources Officer) | Sale | 1,037 | 70.10 | 72,693 |
| 2022-03-08 | Leonard Frank X (Chief Development Officer) | Sale | 744 | 70.10 | 52,154 |
| 2022-03-08 | Cordova Ashley (Chief Financial Officer) | Sale | 759 | 70.10 | 53,205 |
| 2022-03-08 | Shah Pritesh (Chief Commercial Officer) | Sale | 2,481 | 70.10 | 173,918 |
| 2022-03-08 | Longsworth Todd Christopher (General Counsel) | Sale | 2,339 | 70.10 | 163,963 |
| 2022-03-08 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 2,923 | 70.10 | 204,902 |
| 2022-03-08 | Doyle William F (Executive Chairman) | Sale | 2,385 | 70.10 | 167,188 |
| 2022-03-07 | Shah Pritesh (Chief Commercial Officer) | Sale | 5,294 | 69.55 | 368,197 |
| 2022-03-04 | Burke William Patrick (Chief Human Resources Officer) | Sale | 1,026 | 70.41 | 72,237 |
| 2022-03-04 | Leonard Frank X (Chief Development Officer) | Sale | 555 | 70.41 | 39,075 |
| 2022-03-04 | Cordova Ashley (Chief Financial Officer) | Sale | 556 | 70.41 | 39,146 |
| 2022-03-04 | Shah Pritesh (Chief Commercial Officer) | Sale | 4,546 | 71.87 | 326,739 |
| 2022-03-04 | Longsworth Todd Christopher (General Counsel) | Sale | 1,973 | 70.41 | 138,913 |
| 2022-03-04 | Benaim Ely (Chief Medical Officer) | Sale | 1,510 | 70.41 | 106,314 |
| 2022-03-04 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 2,569 | 70.41 | 180,875 |
| 2022-03-03 | Burke William Patrick (Chief Human Resources Officer) | Sale | 341 | 74.50 | 25,403 |
| 2022-03-03 | Leonard Frank X (Chief Development Officer) | Sale | 930 | 74.50 | 69,283 |
| 2022-03-03 | Cordova Ashley (Chief Financial Officer) | Sale | 1,149 | 74.50 | 85,598 |
| 2022-03-03 | Cordova Ashley (Chief Financial Officer) | Option Ex | 5,040 | 13.53 | 68,191 |
| 2022-03-03 | Shah Pritesh (Chief Commercial Officer) | Sale | 997 | 74.50 | 74,274 |
| 2022-03-03 | Longsworth Todd Christopher (General Counsel) | Sale | 1,094 | 74.50 | 81,500 |
| 2022-03-03 | Benaim Ely (Chief Medical Officer) | Sale | 803 | 74.50 | 59,821 |
| 2022-03-03 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 1,301 | 74.50 | 96,921 |
| 2022-01-03 | Burke William Patrick (Chief Human Resources Officer) | Sale | 3,951 | 76.03 | 300,378 |
| 2022-01-03 | Burke William Patrick (Chief Human Resources Officer) | Option Ex | 28,604 | 13.40 | 383,379 |
| 2021-11-26 | Danziger Asaf (Chief Executive Officer) | Buy | 4,974 | 100.74 | 501,095 |
| 2021-11-02 | Cordova Ashley (Chief Financial Officer) | Sale | 209 | 107.28 | 22,420 |
| 2021-09-03 | Shah Pritesh (Chief Commercial Officer) | Sale | 501 | 139.23 | 69,754 |
| 2021-09-02 | Leonard Frank X (Chief Development Officer) | Sale | 540 | 138.23 | 74,645 |
| 2021-09-02 | Cordova Ashley (Chief Financial Officer) | Sale | 828 | 138.23 | 114,456 |
| 2021-09-02 | Shah Pritesh (Chief Commercial Officer) | Sale | 156 | 138.23 | 21,564 |
| 2021-09-02 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 181 | 138.23 | 25,019 |
| 2021-08-12 | Cordova Ashley (Chief Financial Officer) | Sale | 26,624 | 140.93 | 3,752,173 |
| 2021-08-12 | Cordova Ashley (Chief Financial Officer) | Option Ex | 36,624 | 34.13 | 1,249,977 |
| 2021-08-05 | Madden Martin J. | Sale | 34 | 153.13 | 5,206 |
| 2021-08-05 | Leung Gabriel | Sale | 1,000 | 152.50 | 152,500 |
| 2021-08-05 | Leung Gabriel | Option Ex | 1,000 | 31.45 | 31,450 |
| 2021-08-04 | Shah Pritesh (Chief Commercial Officer) | Sale | 2,063 | 148.71 | 306,788 |
| 2021-08-03 | Leonard Frank X (Chief Development Officer) | Sale | 328 | 149.43 | 49,013 |
| 2021-08-03 | Shah Pritesh (Chief Commercial Officer) | Sale | 1,654 | 149.43 | 247,157 |
| 2021-08-03 | Benaim Ely (Chief Medical Officer) | Sale | 464 | 150.11 | 69,651 |
| 2021-08-02 | Leonard Frank X (Chief Development Officer) | Sale | 713 | 149.38 | 106,506 |
| 2021-08-02 | Benaim Ely (Chief Medical Officer) | Sale | 536 | 149.38 | 80,066 |
| 2021-08-02 | Doyle William F (Executive Chairman) | Sale | 995 | 149.38 | 148,631 |
| 2021-07-31 | Shah Pritesh (Chief Commercial Officer) | Option Ex | 3,717 | 154.01 | 572,455 |
| 2021-07-30 | Benaim Ely (Chief Medical Officer) | Sale | 651 | 158.96 | 103,482 |
| 2021-07-30 | Benaim Ely (Chief Medical Officer) | Option Ex | 651 | 83.30 | 54,228 |
| 2021-07-06 | Leung Gabriel | Sale | 1,000 | 183.54 | 183,540 |
| 2021-07-06 | Leung Gabriel | Option Ex | 1,000 | 31.45 | 31,450 |
| 2021-06-10 | Shah Pritesh (Chief Commercial Officer) | Sale | 23,540 | 215.00 | 5,061,100 |
| 2021-06-07 | Leung Gabriel | Sale | 1,000 | 204.55 | 204,550 |
| 2021-06-07 | Leung Gabriel | Option Ex | 1,000 | 31.45 | 31,450 |
| 2021-05-27 | Benaim Ely (Chief Medical Officer) | Sale | 1,833 | 200.00 | 366,600 |
| 2021-05-27 | Benaim Ely (Chief Medical Officer) | Option Ex | 1,833 | 47.56 | 87,177 |
| 2021-05-12 | Benaim Ely (Chief Medical Officer) | Sale | 1,943 | 180.48 | 350,672 |
| 2021-05-11 | Benaim Ely (Chief Medical Officer) | Sale | 2,262 | 180.12 | 407,426 |
| 2021-05-10 | Benaim Ely (Chief Medical Officer) | Sale | 1,833 | 189.65 | 347,628 |
| 2021-05-10 | Benaim Ely (Chief Medical Officer) | Option Ex | 1,833 | 47.56 | 87,177 |
| 2021-05-05 | Leung Gabriel | Sale | 1,000 | 199.67 | 199,670 |
| 2021-05-05 | Leung Gabriel | Option Ex | 1,000 | 31.45 | 31,450 |
| 2021-04-13 | Danziger Asaf (Chief Executive Officer) | Sale | 97,973 | 196.34 | 19,236,312 |
| 2021-04-13 | Benaim Ely (Chief Medical Officer) | Sale | 5,958 | 200.00 | 1,191,600 |
| 2021-04-13 | Benaim Ely (Chief Medical Officer) | Option Ex | 5,958 | 66.74 | 397,654 |
| 2021-04-13 | Leung Gabriel | Sale | 6,000 | 199.00 | 1,194,030 |
| 2021-04-13 | Leung Gabriel | Option Ex | 6,000 | 31.45 | 188,700 |
| 2021-04-01 | Doyle William F (Executive Chairman) | Sale | 7,928 | 134.12 | 1,063,303 |
| 2021-03-31 | Doyle William F (Executive Chairman) | Option Ex | 9,259 | 125.25 | 1,159,689 |
| 2021-03-09 | Shah Pritesh (Chief Commercial Officer) | Sale | 3,524 | 131.09 | 461,961 |
| 2021-03-08 | Leonard Frank X (Chief Development Officer) | Sale | 765 | 130.81 | 100,066 |
| 2021-03-08 | Cordova Ashley (Chief Financial Officer) | Sale | 765 | 130.81 | 100,066 |
| 2021-03-08 | Shah Pritesh (Chief Commercial Officer) | Sale | 2,627 | 130.81 | 343,627 |
| 2021-03-08 | Longsworth Todd Christopher (General Counsel) | Sale | 2,404 | 130.81 | 314,457 |
| 2021-03-08 | Groenhuysen Wilhelmus Cm (Chief Operating Officer) | Sale | 3,004 | 130.81 | 392,941 |
| 2021-03-05 | Shah Pritesh (Chief Commercial Officer) | Sale | 4,550 | 131.53 | 598,461 |
| 2021-03-05 | Shah Pritesh (Chief Commercial Officer) | Option Ex | 13,987 | 7.15 | 100,007 |
Insider trading activities including stock purchases, stock sales, and option exercises of NVCR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Novocure Ltd (symbol NVCR, CIK number 1645113) see the Securities and Exchange Commission (SEC) website.